Elegen

Elegen is a synthetic biology company that has developed the world's only entirely cell-free platform for rapid, high-quality DNA production, using microfluidics, AI, and robotics to deliver long, clonal-quality, high-complexity DNA products with unprecedented speed, low costs, and efficiency. The company's patented ENFINIA DNA platform eliminates the need for cells, cloning, and foundries, producing NGS-verified linear DNA with 99.999% per base accuracy (1:70,000 bp error rate) in 6-8 business days, up to 7 kb in length, ready for immediate use without cloning. The product portfolio includes ENFINIA Linear DNA, which arrives NGS-verified and ready to use without colony screening or additional sequencing, and ENFINIA IVT Ready DNA, designed for mRNA therapeutics development with encoded poly(A) tails delivered up to three times faster and free from bioburden, endotoxins, and recombination-mediated variation. Elegen's Gen II Cell Free Platform incorporates the world's first directed split-pool microfluidic synthesizer combined with patented cell-free cloning technology, fully automating production of long, clonal-quality, high-complexity double-stranded DNA. The platform serves applications in cell and gene therapy, genome editing, mRNA prophylactic vaccines, mRNA personalized cancer vaccines, and protein expression, with pricing as low as $0.07 per base pair. Founded in 2017 and headquartered in San Carlos, California, Elegen has raised $35.0M in Series B funding from investors including Triatomic, GSK, Andreessen Horowitz, KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures, Agilent, HHS, and Sahsen Ventures.